RSV Vaccine Now Killing Babies — VAERS Reports

Babies died after receiving cocktail of dangerous RSV vaccine intended for old folks on top of the already dangerous RSV monoclonal antibody drug injection.

At least two infants died after they were mistakingly given Pfizer’s respiratory syncytial virus (RSV) vaccine along with Nirsevimab, a monoclonal antibody injection approved for infants that’s meant to prevent RSV.

A 29-day-old premature girl died after receiving an RSV shot meant for the elderly, according to the Vaccine Adverse Event Reporting System (VAERS).

“According to the mother, the patient departed the clinic at 1 pm after the vaccine was administered. Subsequently, the patient took a nap and at approximately 8 pm, the father observed that the patient was not breathing. The parents attempted CPR but it was unsuccessful,” the VAERS report said. “Shortly thereafter, the parents called both ambulance and police assistance. Upon the paramedics” arrival, the patient had already deceased; The causes of death are unknown, An autopsy is presently in the process of being investigated. The mother has not yet reported the exact cause of death, information was given via a telephone call.”

A 27-day-old boy also received the RSV shot, which resulted in a similar fate.

“Her son was only 27 days old and received the vaccine at doctor”s office and he passed away right there; Her son was only 27 days old and received the vaccine at doctor”s office and he passed away right there; This is a spontaneous report received from a Consumer or other non HCP. A 27-day-old male patient received rsv vaccine prot.subunit pref 2v (ABRYSVO), as dose number unknown, single (Batch/Lot number: unknown) for immunisation. The patient”s relevant medical history and concomitant medications were not reported,” the VARES report said. “The following information was reported: DEATH (death, medically significant), outcome “fatal”, PRODUCT USE ISSUE (non-serious), outcome “unknown” and all described as “Her son was only 27 days old and received the vaccine at doctor”s office and he passed away right there”. The date and cause of death for the patient were unknown. It was not reported if an autopsy was performed. The information on the batch/lot number for rsv vaccine prot.subunit pref 2v, rsv vaccine prot.subunit pref 2v will be requested and submitted if and when received.; Reported Cause(s) of Death: Her son was only 27 days old and received the vaccine at doctor”s office and he passed away right there.”

Notably, the monoclonal antibody Beyfortus (also known as Nirsevimab) which is produced by Sanofi and AstraZeneca also has a checkered safety record.

The monoclonal antibody is intended to be injected into infants born during the ‘RSV season’ and marketed as a ‘powerful tool’.

Interestingly, even when the RSV vaccine is given to the target demographic, seniors, a medical study said the RSV-vaccinated experienced allergic reactions as well as serious heart and nervous system disorders.

“At the data-cutoff date, 2.3% of the vaccine recipients and 2.3% of the placebo recipients had reported serious adverse events, and three of these events were considered by the investigators to be related to the trial intervention. The first serious adverse event was a delayed allergic reaction 7 hours after injection of RSVpreF vaccine, with recovery on the same day. The second serious adverse event was a combination of diplopia, paresthesia of palms and soles, and oculomotor and abducens nerve paralysis 8 days after injection in a participant in the vaccine group who had a medical history of diabetes mellitus; this event was retrospectively diagnosed as being consistent with the Miller–Fisher syndrome (a subset of the Guillain–Barré syndrome characterized by ophthalmoplegia, ataxia, and areflexia). A spinal tap and nerve-conduction studies were not performed, and the participant recovered,” the study said in the ‘Safety’ section. “The last serious adverse event, also in a participant in the vaccine group, was myocardial infarction that developed 6 days after injection. This participant then underwent angioplasty and later received a diagnosis of acute inflammatory demyelinating polyradiculoneuropathy, consistent with Guillain–Barré syndrome, that began 7 days after injection. The participant continued to recover and regained most motor function. No trial intervention–related deaths or adverse events leading to withdrawal from the trial were reported.”

While the RSV vaccine the infants received was a classic vaccine, Moderna recently had their mRNA-based RSV vaccine approved for human use, set to be injected into patients later this year.

BREAKING: Biden Pledges To Never Leave, Throwing Deep State Into Panic